NKGen’s Alzheimer’s Therapy Eyes China Amid a Regulatory Revolution

SANTA ANA, CA – July 02, 2026 – When a biotech CEO travels to a major international forum, it’s rarely just for the scientific accolades. NKGen Biotech’s announcement that its Chairman and CEO, Dr. Paul Y. Song, will present at the 2026 BIOCHINA Global Forum is a case in point. While the presentation will highlight the clinical progress of its lead candidate, troculeucel, for Alzheimer’s disease, the real story lies in the strategic undercurrent: a calculated move to engage with one of the world’s fastest-evolving and most promising healthcare markets.

This isn’t just about sharing data; it’s about signaling intent. NKGen is positioning its innovative natural killer (NK) cell therapy to capitalize on China's radical new regulatory frameworks, potentially accelerating its path from a U.S. clinical-stage asset to a commercial therapy available to millions in Asia. The presentation in Seoul is a clear overture to potential partners, regulators, and investors, indicating that the future of this promising neurodegenerative treatment may be forged through cross-pacific collaboration.

A New Frontier in Neurodegeneration: The Science of Troculeucel

At the heart of NKGen’s strategy is troculeucel, a novel, patient-specific immunotherapy that harnesses the body’s own natural killer cells. Unlike many treatments that simply manage symptoms, this therapy represents a fundamental shift in how we might tackle neurodegenerative diseases. The process involves isolating a patient's own NK cells, expanding and activating them outside the body, and then reinfusing this supercharged immune force. This autologous approach minimizes the risk of rejection and is designed to directly intervene in the disease process.

The therapy's proposed mechanism is what sets it apart. Research suggests troculeucel’s enhanced NK cells can cross the notoriously difficult blood-brain barrier. Once inside the central nervous system, they are believed to perform two critical functions: reducing the chronic neuroinflammation that is a key driver of neuronal damage and actively clearing the toxic protein aggregates—such as amyloid-beta and tau—that are hallmarks of Alzheimer's. In essence, it’s a 'seek and destroy' mission combined with a powerful anti-inflammatory response.

Promising data from the company's Phase 1 trial has already provided a glimpse of this potential. The therapy was well-tolerated, and a remarkable 90% of evaluable subjects showed stable or improved cognitive scores. More importantly, analysis of cerebrospinal fluid showed beneficial changes in key biomarkers, including a reduction in phosphorylated tau (pTau181) and glial fibrillary acidic protein (GFAP), which are indicators of neuronal injury and inflammation. The company is now advancing a Phase 2 trial for moderate Alzheimer's, a stage of the disease with desperately few options.

But the ambition for troculeucel extends far beyond a single condition. Dr. Song’s presentation will also cover its potential application for other devastating neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Parkinson’s disease. By targeting common pathological pathways like protein aggregation and neuroinflammation, NKGen is developing a platform, not just a product, with the potential to redefine treatment across a spectrum of neurological disorders.

The Strategic Pivot to Asia: Navigating China's Biotech Landscape

Dr. Song’s planned discussion on China’s regulatory environment is the most strategically significant part of the announcement. In recent years, China has aggressively overhauled its policies to become a global hub for biomedical innovation. This isn't just about streamlining old processes; it's about creating entirely new, accelerated pathways to bring cutting-edge therapies to patients.

One of the most transformative developments is the establishment of special medical zones, such as the Hainan Boao Lecheng International Medical Tourism Pilot Zone. Within these zones, therapies that have shown promise in U.S. or European trials—even those in Phase 2, like troculeucel—can be used to treat patients under a special fast-track procedure. This allows companies to generate crucial real-world data on Chinese patients, which can then be used to support a broader New Drug Application with China's National Medical Products Administration (NMPA). It’s a powerful mechanism for de-risking and accelerating market entry.

Furthermore, China recently relaxed foreign investment restrictions in key free-trade zones, permitting foreign-invested firms to engage in the development and application of cell and gene therapies. This opens the door for companies like NKGen to establish a more direct presence, whether through wholly-owned subsidiaries or joint ventures. Dr. Song’s presentation is a clear exploration of these opportunities, aimed at attracting the Chinese pharmaceutical companies and contract development and manufacturing organizations (CDMOs) that could become vital partners.

Addressing a Vast Unmet Need

The strategic importance of this move is underscored by the immense unmet need. While the recent approval of amyloid-clearing drugs like Leqembi offered a long-awaited breakthrough for early-stage Alzheimer's, their impact is limited. These treatments require frequent intravenous infusions, carry risks of side effects like brain swelling or bleeding (ARIA), and are not intended for patients with moderate or advanced disease. The market is crying out for therapies with different mechanisms of action, easier administration, and efficacy across a wider range of patients.

Troculeucel, by targeting neuroinflammation and showing potential in moderate Alzheimer's, could fill a critical gap. The same applies to ALS and Parkinson's, where existing treatments offer only modest symptomatic relief and fail to halt the relentless progression of the disease. A therapy that could potentially modify the disease course by cleaning up the underlying pathology would be nothing short of revolutionary for patients and their families.

By engaging with the BIOCHINA forum, NKGen is not only showcasing its science but also its deep understanding of the global healthcare landscape. The company recognizes that bringing a complex, personalized cell therapy to market requires more than just successful clinical trials. It demands a sophisticated strategy for manufacturing, logistics, and market access. Forging partnerships in Asia, particularly China, could provide the scale, resources, and regulatory runway needed to make troculeucel a global reality, offering a new beacon of hope for millions grappling with the darkness of neurodegeneration.